A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (The Auto-CAR19 Trial).

大多数白血病和淋巴瘤患者在化疗后早期复发，死于他们的疾病。将特殊基因植入免疫细胞可以使它们杀死白血病和淋巴瘤，并带来了戏剧性的治愈，但用于制造这些细胞的病毒载体的成本高得令人望而却步。我们将使用一种廉价的非病毒系统从白血病和淋巴瘤患者中提取特异性免疫细胞，然后将这些免疫细胞用于患者，以评估其安全性和有效性。

Most people with leukaemia and lymphoma who relapse early after chemotherapy die of their disease. Inserting special genes into immune cells can enable them to kill leukaemia and lymphoma and has led to dramatic cures, but the cost of the viral vectors used to make these cells is prohibitively expensive. We will make leukaemia and lymphoma specific immune cells from patients using an inexpensive non-viral system, then administer the immune cells to patients to assess their safety and efficacy.